Prescott Group Capital Management L.L.C. Invests $4.81 Million in GoodRx Holdings, Inc. $GDRX

Prescott Group Capital Management L.L.C. purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,775,502 shares of the company’s stock, valued at approximately $4,812,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of GDRX. LSV Asset Management boosted its stake in shares of GoodRx by 517.1% in the 3rd quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock worth $9,960,000 after buying an additional 1,973,017 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of GoodRx by 10,242.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock worth $4,072,000 after buying an additional 1,488,137 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in GoodRx in the 3rd quarter worth $3,036,000. Vanguard Group Inc. raised its holdings in GoodRx by 7.3% in the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock worth $38,947,000 after purchasing an additional 624,182 shares during the period. Finally, Moore Capital Management LP bought a new position in GoodRx in the 3rd quarter worth $2,217,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Price Performance

NASDAQ:GDRX opened at $2.52 on Thursday. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. The business’s 50-day simple moving average is $2.29 and its two-hundred day simple moving average is $2.51. The stock has a market cap of $863.29 million, a PE ratio of 42.01, a P/E/G ratio of 1.61 and a beta of 1.54. GoodRx Holdings, Inc. has a 52 week low of $1.77 and a 52 week high of $5.81.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07. The business had revenue of $194.01 million for the quarter, compared to analysts’ expectations of $185.40 million. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The business’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $0.09 earnings per share. As a group, analysts forecast that GoodRx Holdings, Inc. will post 0.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GDRX shares. Wells Fargo & Company decreased their target price on GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Wall Street Zen cut GoodRx from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Weiss Ratings raised GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GoodRx in a report on Friday, February 27th. Finally, Jefferies Financial Group cut GoodRx to a “hold” rating in a report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, GoodRx currently has a consensus rating of “Hold” and a consensus price target of $3.81.

GoodRx Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.